Loading
A phase 2 trial of enfortumab vedotin in colorectal cancer, run by H. Lee Moffitt Cancer Center and Research Institute, now recruiting.
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC is a phase 2, interventional study registered as NCT06553885 by H. Lee Moffitt Cancer Center and Research Institute, with a registry enrolment figure of 40 participants, started 2025-04-01 and due to reach its primary completion in 2029-09. Interventions recorded: Enfortumab Vedotin. Conditions listed: Metastatic Colorectal Cancer; Hepatocellular Carcinoma. Primary outcome: Overall response rate (ORR). Sites: United States. No results are recorded here; the registry entry is the source.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.